[1]聂俊玲,江小华,刘庆春,等.重组人干扰素α2a栓联合康妇凝胶治疗对高危型HPV感染患者免疫功能及转阴率的影响[J].医学信息,2024,37(21):70-73.[doi:10.3969/j.issn.1006-1959.2024.21.015]
 NIE Junling,JIANG Xiaohua,LIU Qingchun,et al.Effect of Recombinant Human Interferon α2a Suppository Combined with Kangfu Gel on Immune Function and Negative Conversion Rate in Patients with High-risk HPV Infection[J].Journal of Medical Information,2024,37(21):70-73.[doi:10.3969/j.issn.1006-1959.2024.21.015]
点击复制

重组人干扰素α2a栓联合康妇凝胶治疗对高危型HPV感染患者免疫功能及转阴率的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年21期
页码:
70-73
栏目:
论著
出版日期:
2024-11-01

文章信息/Info

Title:
Effect of Recombinant Human Interferon α2a Suppository Combined with Kangfu Gel on Immune Function and Negative Conversion Rate in Patients with High-risk HPV Infection
文章编号:
1006-1959(2024)21-0070-04
作者:
聂俊玲江小华刘庆春邓娟华
峡江县妇幼保健计划生育服务中心妇产科,江西 峡江 331400
Author(s):
NIE JunlingJIANG XiaohuaLIU QingchunDENG Juanhua
Department of Obstetrics and Gynecology,Xiajiang County Maternal and Child Health Family Planning Service Center,Xiajiang 331400,Jiangxi,China
关键词:
高危型HPV感染重组人干扰素α2a栓康妇凝胶免疫功能
Keywords:
High-risk HPV infectionRecombinant human interferon α2a suppositoryKangfu gelImmune function
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2024.21.015
文献标志码:
A
摘要:
目的 研究重组人干扰素α2a(rhIFN-α2a)栓联合康妇凝胶治疗对提高高危型人乳头瘤病毒(HPV)感染患者免疫功能及转阴率的意义。方法 以2021年1月-2023年3月峡江县妇幼保健计划生育服务中心收治的60例高危型HPV感染患者为研究对象,行随机数字表法分为对照组(30例)与观察组(30例)。对照组采用rhIFN-α2a栓治疗,观察组在对照组基础上联合康妇凝胶治疗,比较两组临床疗效、免疫功能(CD8+、CD4+、CD4+/CD8+)、炎症因子[转化生长因子-β1(TGF-β1)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]、HPV转阴率与HPV感染复发率。结果 观察组治疗总有效率为96.67%,高于对照组的80.00%(P<0.05);两组治疗后CD4+、CD4+/CD8+高于治疗前,且观察组治疗后CD4+、CD4+/CD8+高于对照组(P<0.05);两组治疗后TGF-β1、IL-6、TNF-α水平低于治疗前,且观察组治疗后TGF-β1、IL-6、TNF-α水平低于对照组(P<0.05);观察组HPV转阴率高于对照组,且HPV感染复发率低于对照组(P<0.05)。结论 rhIFN-α2a栓联合康妇凝胶在高危型HPV感染治疗中具有良好疗效,可增强患者免疫功能,减轻机体炎症反应,提高其HPV转阴率,降低复发风险。
Abstract:
Objective To study the significance of recombinant human interferon α2a (rhIFN-α2a) suppository combined with Kangfu gel in improving the immune function and negative conversion rate of patients with high-risk human papillomavirus (HPV) infection.Methods A total of 60 patients with high-risk HPV infection admitted to Xiajiang County Maternal and Child Health Care and Family Planning Service Center from January 2021 to March 2023 were enrolled in the study. They were divided into control group (30 patients) and observation group (30 patients) by random number table method. The control group was treated with rhIFN-α2 a suppository, and the observation group was treated with Kangfu gel on the basis of the control group. The clinical efficacy, immune function (CD8+, CD4+, CD4+/CD8+), inflammatory factors [transforming growth factor-β1 (TGF-β1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)], HPV negative conversion rate and HPV infection recurrence rate were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.67%, which was higher than 80.00% in the control group (P<0.05). After treatment, CD4+ and CD4+/CD8+ in the two groups were higher than those before treatment, and CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group (P<0.05). After treatment, the levels of TGF-β1, IL-6 and TNF-α in the two groups were lower than those before treatment, and the levels of TGF-β1, IL-6 and TNF-α in the observation group were lower than those in the control group (P<0.05). The negative conversion rate of HPV in the observation group was higher than that in the control group, and the recurrence rate of HPV infection was lower than that in the control group (P<0.05).Conclusion rhIFN-α2a suppository combined with Kangfu gel has a good effect in the treatment of high-risk HPV infection, which can enhance the immune function of patients, reduce the body’s inflammatory response, improve the HPV negative rate and reduce the risk of recurrence.

参考文献/References:

[1]陈庆,张妮,胡晓琴,等.重组人干扰素α2a栓对人乳头瘤病毒感染患者宫颈黏液中炎性因子水平的影响[J].中国生物制品学杂志,2023,36(7):810-814.[2]吴希文,杨开宇,郭新,等.重组人干扰素α2a栓剂对宫颈人乳头瘤病毒清除效果的观察[J].中国生物制品学杂志,2018,31(7):744-747.[3]姜歆宇,岳亚琳.保妇康栓联合重组人干扰素α-2b对慢性宫颈炎合并HPV感染患者HPV转阴的影响[J].中国妇幼保健,2022,37(20):3753-3756.[4]唐宇星,王敏,张诗敏,等.不同药物对高危型HPV持续感染及宫颈癌前病变合并高危型HPV感染的临床疗效对比研究[J].实用药物与临床,2022,25(5):385-391.[5]王茜,方晓华,陈婷婷.保妇康栓联合干扰素栓治疗HPV感染的效果分析[J].沈阳药科大学学报,2021,38(1):48.[6]朱丽芳,徐燕.保妇康栓联合干扰素α-2b治疗慢性宫颈炎合并人乳头瘤病毒感染的疗效[J].海军医学杂志,2021,42(3):343-346.[7]王运萍,徐佳,李砚,等.保妇康栓联合干扰素栓对高危型人乳头瘤病毒感染患者的效果及HPV-DNA、炎性因子、免疫功能的变化[J].贵州医药,2021,45(1):39-40.[8]李玉仙.重组人干扰素α-2b栓联合保妇康栓对慢性宫颈炎合并人乳头瘤病毒感染的疗效观察[J].中国药物与临床,2020,20(14):2385-2387.[9]苏小玉,蒙莉萍,邹聪聪,等.重组人干扰素凝胶联合保妇康栓治疗宫颈高危型HPV感染的临床观察[J].中国药房,2020,31(8):984-988.[10]于淼淼,杨露.抗妇炎胶囊联合重组人干扰素α2b对慢性宫颈炎伴HPV感染患者的临床疗效[J].中成药,2020,42(1):89-93.[11]白娅琴,秦丽欣,李妍,等.易黄汤加味联合重组人干扰素α-2b栓治疗慢性宫颈炎伴高危型人乳头瘤病毒感染患者病毒载量疗效观察[J].湖北中医药大学学报,2022,24(5):113-115.[12]赵秀梅,金玲,常春玲,等.复方沙棘籽油栓联合重组人干扰素α2b栓治疗人乳头瘤病毒感染合并慢性宫颈炎的效果及对患者免疫功能和炎性因子水平的影响[J].中国医药,2019,14(11):1689-1693.[13]韩亚琴,张玲玲,代庆林,等.重组人干扰素α-2b栓联合保妇康栓治疗慢性宫颈炎合并高危型HPV感染的临床研究[J].川北医学院学报,2019,34(3):422-424.[14]高新源,王慧颖.康妇凝胶治疗高危型宫颈人乳头瘤病毒感染的临床研究[J].河北中医药学报,2019,34(3):21-23.[15]王转红,王峥,刘欢,等.康复新液联合保妇康栓治疗慢性宫颈炎伴HPV感染疗效观察[J].中医学报,2018,33(8):1576-1579.[16]贾利平,刘玉珠,周小飞,等.重组人干扰素α-2b联合保妇康栓对HPV感染患者的治疗效果[J].中华医院感染学杂志,2019,29(5):749-752.[17]武春梅,张爱英.保妇康栓联合重组人干扰素α-2b治疗慢性宫颈炎合并高危型HPV感染临床研究[J].湖北中医药大学学报,2019,21(6):69-71.[18]涂春艳,龚兰,许小凤.康妇凝胶治疗慢性子宫颈炎合并人乳头瘤病毒感染的临床疗效评价[J].实用临床医药杂志,2018,22(9):113-114,117.[19]冯小丽,刘继红,李聪.重组人干扰素α-2b与保妇康栓阴道放置对宫颈高危HPV感染患者的疗效及免疫功能的影响[J].河北医药,2018,40(7):1083-1085.[20]麦燕,麦燕婷.重组人干扰素α-2b联合保妇康栓治疗慢性宫颈炎合并人乳头瘤病毒感染效果分析[J].山西医药杂志,2018,47(3):283-284.[21]包存芳,陈冀莹,张惠玲,等.保妇康栓联合干扰素栓对宫颈HPV感染患者的效果及HPV DNA、炎性因子、免疫功能的变化[J].解放军预防医学杂志,2019,37(2):149-150.[22]雷露,汪海燕.康妇凝胶治疗宫颈人乳头状瘤病毒(HPV)感染临床研究[J].陕西中医,2021,42(1):40-41.

相似文献/References:

[1]刘晓莲.重组人干扰素α-2b阴道泡腾片联合保妇康栓治疗宫颈癌前病变合并高危型HPV感染的疗效[J].医学信息,2024,37(06):143.[doi:10.3969/j.issn.1006-1959.2024.06.025]
 LIU Xiao-lian.Efficacy of Recombinant Human Interferon α-2b Vaginal Effervescent Capsule Combined with Baofukang Suppository in the Treatment of Cervical Precancerous Lesions with High-risk HPV Infection[J].Journal of Medical Information,2024,37(21):143.[doi:10.3969/j.issn.1006-1959.2024.06.025]
[2]彭雪琴.宫颈上皮内瘤变宫颈锥切术后复发的影响因素分析[J].医学信息,2025,38(05):136.[doi:10.3969/j.issn.1006-1959.2025.05.023]
 PENG Xueqin.Analysis of Influencing Factors of Recurrence After Cervical Conization of Cervical Intraepithelial Neoplasia[J].Journal of Medical Information,2025,38(21):136.[doi:10.3969/j.issn.1006-1959.2025.05.023]

更新日期/Last Update: 1900-01-01